WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Atlas Genetics
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
PRNewswire | June 12, 2023
BioCentriq®, a strategic CDMO specializing in cell therapy announced that it has expanded its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). The partnership was originally announced in March of 2021. In the initial phase of the collaboration, the Kytopen and BioCentriq teams worked together to test transfection of T-cells using Kytopen's Flowfect® technology and the potential impact to both autologous and ...
BioSpace | March 20, 2020
EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....
Dyadic International, Inc. | December 23, 2021
Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...
Pulmatrix, Inc. | September 27, 2022
Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE